Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03760523 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03760523 is a Phase 1 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 27 participants.
The verdict
NCT03760523, a Phase 1 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study is to determine the safety and recommended dosing of Minnelide in Acute Myeloid Leukemia (AML)
Interventions
- DRUG Minnelide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-04-18 |
| Est. Completion | 2023-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03760523
The ClinicalTrials.gov registry entry for NCT03760523 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Minnelide is the first listed.
NCT03760523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03760523 about?
NCT03760523 is a clinical study titled "Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia". This study is to determine the safety and recommended dosing of Minnelide in Acute Myeloid Leukemia (AML)
What is the current status of trial NCT03760523?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2019-04-18. Estimated completion is 2023-10-09.
What interventions are being tested in trial NCT03760523?
The interventions under investigation include: Minnelide (DRUG).
Who is sponsoring clinical trial NCT03760523?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.